Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: A US perspective

American Journal of Managed Care

Volumn 8, Issue 12, 2002, Pages 1082-1088

  De Lissovoy, Gregory ^a   Subedi, Prasun ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO;

ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DISEASE SEVERITY; DISEASE SIMULATION; DOUBLE BLIND PROCEDURE; DRUG COST; ECONOMIC EVALUATION; FUTUROLOGY; HEALTH CARE; HIGH RISK PATIENT; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MODEL; OUTPATIENT CARE; PATIENT CARE; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; RESOURCE ALLOCATION; THROMBOCYTOPENIA; THROMBOEMBOLISM; UNITED STATES; VEIN THROMBOSIS;

ANTICOAGULANTS; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; DRUG COSTS; ENOXAPARIN; HOSPITAL COSTS; HOSPITALIZATION; HUMANS; PREMEDICATION; THROMBOEMBOLISM; UNITED STATES; VENOUS THROMBOSIS;

EID: 0036916070     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Linblad B, Sternby NH, Bergqvist D, et al. Incidence of venous thromboembolism verified by necropsy over 30 years. BMJ. 1991;302:709-711.
2. Sandler DA, Martin JF, et al. Autopsy proven pulmonary embolism in hospital patients: Are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82:203-205.
3. Clagett GP, Anderson FA, Heit JA, et al. Prevention of venous thromboembolism. Chest. 1998;114(suppl):531S-560S.
4. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341:793-800.
5. Geerts W, Heit J, Clagett G, et al. Prevention of venous thromboembolism. Chest. 2001;119:132S-175S.
6. Cohen AT, Zaw HM, Alikhan R. Benefits of deep-vein thrombosis prophylaxis in the nonsurgical patients: The MEDENOX trial. Semin Hematol. 2001;38(2 suppl 5):31-38.
7. InpatientView™ National Hospital Discharge Database. Baltimore, MD: HCIA Sachs; 1998.
8. Redbook ReadyPrice® System. Greenwood, CO: MicroMedex Division, Thomson Health Care; 2002.
9. Healthcare Consultants of America. Physicians' Fee and Coding Guide. Augusta. GA: MAG Mutual Group; 1999.
10. Health Care Financing Administration. Home health agency cost limits data set. 1999. Available at: http://www.hcfa.gov/stats/pufiles.htm. Public Use File hhacyc16.exe. Accessed January 30, 2001.
11. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep vein thrombosis. N Engl J Med. 1996;334:682-687.
12. Lloyd AC, Anderson PM, Quinlan DJ, Bearne A. Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients. J Med Econ. 2001;4:99-113.
13. Pechivis M, Detournay B, Pribil C, Fagnani F, Chalanson C. Economic evaluation of enoxaparin vs placebo for the prevention of venous thrombosis in acutely ill medical patients. Value in Health. 2001;3(6):389-396.
14. De Lissovoy G, Yusen RD, Spiro TE, et al. Cost for inpatient care of venous thrombosis. Arch Intern Med. 2000;160:3161-3164.
15. Gould MK, Dembitzer AD, Doyle RL, Sanders GD, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. Ann Intern Med. 1992;130(10):789-799.
16. Spyropolous A, Hurley JS, Ciesla GN, De Lissovoy G. Management of acute proximal deep vein thrombosis: Pharmacoeconomic evaluation of outpatient treatment with enoxaparin versus unfractionated heparin. Chest. 2002;122:108-114.
17. Geerts W, Heit J, Clagett GP, et al. Prevention of venous thromboembolism. Sixth ACCP Consensus Conference on Antithrombotic Therapy. Chest. 2001;119(1 suppl):132S-175S.
18. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalized medical patients. J Clin Pathol. 1997;50:609-610.
19. Prandoni P, Villalta S, Bagatella P, et al. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients. Haematologica. 1997;82:423-428.
20. Bernardi E, Prandoni P. The post-thrombotic syndrome. Curr Opin Pulm Med. 2000;6(4):335-342.
21. Kahn S, Solymoss S, Lamping D, et al. Long-term outcomes after deep vein thrombosis: Postphlebitic syndrome and quality of life. J Gen Intern Med. 2000;15(6):425-429.